Literature DB >> 24304379

Comprehensive health assessment and five-yr follow-up of allogeneic islet transplant recipients.

D M Radosevich1, R Jevne, M Bellin, R Kandaswamy, D E R Sutherland, B J Hering.   

Abstract

In patients with type 1 diabetes mellitus (T1DM) complicated by severe hypoglycemic episodes, fear of hypoglycemia can significantly impact daily life. We evaluated whether restoration of glycemic awareness and prevention of hypoglycemia by islet allotransplant could reduce fear and improve health status. We conducted a comprehensive evaluation of patient-based outcomes in 48 T1DM subjects screened for allogeneic islet transplant alone (ITA) and 27 subjects who received an ITA. A battery of generic health status and diabetes-specific measures were used to assess ITA at evaluation, six months, and then annually after ITA. Allogeneic islet transplant was associated with a reduction in behaviors adopted in avoiding hypoglycemia (p Value < 0.001) and attenuation in concerns about hypoglycemic episodes (p Value < 0.001). Changes in hypoglycemia fear tracked most closely with insulin use. While there was a trend toward global improvement in health as measured by the EQ-5D (p Value = 0.002) and in depression symptoms as measured by the Beck (p Value = 0.003), physical health remained unchanged following ITA. Our findings support the socioemotional benefits of ITA during the five years after ITA, which to some extent remains dependent on preservation of islet graft function.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  allogeneic islet transplant; hypoglycemia fear; outcomes assessment (health care); quality of life; type 1 diabetes mellitus

Mesh:

Substances:

Year:  2013        PMID: 24304379      PMCID: PMC4132880          DOI: 10.1111/ctr.12265

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  24 in total

1.  The Problem Areas in Diabetes Scale. An evaluation of its clinical utility.

Authors:  G W Welch; A M Jacobson; W H Polonsky
Journal:  Diabetes Care       Date:  1997-05       Impact factor: 19.112

2.  Reduced fear of hypoglycemia in successful islet transplantation.

Authors:  Jeffrey A Johnson; Maria Kotovych; Edmond A Ryan; A M James Shapiro
Journal:  Diabetes Care       Date:  2004-02       Impact factor: 19.112

3.  Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes.

Authors:  M D Bellin; R Kandaswamy; J Parkey; H-J Zhang; B Liu; S H Ihm; J D Ansite; J Witson; P Bansal-Pakala; A N Balamurugan; K K Papas; K Papas; D E R Sutherland; A Moran; B J Hering
Journal:  Am J Transplant       Date:  2008-09-19       Impact factor: 8.086

4.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

5.  Multiple comparisons and related issues in the interpretation of epidemiologic data.

Authors:  D A Savitz; A F Olshan
Journal:  Am J Epidemiol       Date:  1995-11-01       Impact factor: 4.897

6.  Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study.

Authors:  J E Ware; M Kosinski; M S Bayliss; C A McHorney; W H Rogers; A Raczek
Journal:  Med Care       Date:  1995-04       Impact factor: 2.983

7.  Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen.

Authors:  A M Shapiro; J R Lakey; E A Ryan; G S Korbutt; E Toth; G L Warnock; N M Kneteman; R V Rajotte
Journal:  N Engl J Med       Date:  2000-07-27       Impact factor: 91.245

8.  Assessment of diabetes-related distress.

Authors:  W H Polonsky; B J Anderson; P A Lohrer; G Welch; A M Jacobson; J E Aponte; C E Schwartz
Journal:  Diabetes Care       Date:  1995-06       Impact factor: 19.112

9.  Fear of hypoglycemia: quantification, validation, and utilization.

Authors:  D J Cox; A Irvine; L Gonder-Frederick; G Nowacek; J Butterfield
Journal:  Diabetes Care       Date:  1987 Sep-Oct       Impact factor: 19.112

10.  Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody.

Authors:  Bernhard J Hering; Raja Kandaswamy; James V Harmon; Jeffrey D Ansite; Sue M Clemmings; Tetsuya Sakai; Stephen Paraskevas; Peter M Eckman; Junichiro Sageshima; Masahiko Nakano; Toshiya Sawada; Ippei Matsumoto; Hui J Zhang; David E R Sutherland; Jeffrey A Bluestone
Journal:  Am J Transplant       Date:  2004-03       Impact factor: 8.086

View more
  9 in total

Review 1.  Defining Outcomes for β-cell Replacement Therapy in the Treatment of Diabetes: A Consensus Report on the Igls Criteria From the IPITA/EPITA Opinion Leaders Workshop.

Authors:  Michael R Rickels; Peter G Stock; Eelco J P de Koning; Lorenzo Piemonti; Johann Pratschke; Rodolfo Alejandro; Melena D Bellin; Thierry Berney; Pratik Choudhary; Paul R Johnson; Raja Kandaswamy; Thomas W H Kay; Bart Keymeulen; Yogish C Kudva; Esther Latres; Robert M Langer; Roger Lehmann; Barbara Ludwig; James F Markmann; Marjana Marinac; Jon S Odorico; François Pattou; Peter A Senior; James A M Shaw; Marie-Christine Vantyghem; Steven White
Journal:  Transplantation       Date:  2018-09       Impact factor: 4.939

2.  Improved Health-Related Quality of Life in a Phase 3 Islet Transplantation Trial in Type 1 Diabetes Complicated by Severe Hypoglycemia.

Authors:  Eric D Foster; Nancy D Bridges; Irene D Feurer; Thomas L Eggerman; Lawrence G Hunsicker; Rodolfo Alejandro
Journal:  Diabetes Care       Date:  2018-03-21       Impact factor: 19.112

Review 3.  Pancreatic Islet Transplantation in Humans: Recent Progress and Future Directions.

Authors:  Michael R Rickels; R Paul Robertson
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

4.  Islet cell transplant: Update on current clinical trials.

Authors:  Christian Schuetz; James F Markmann
Journal:  Curr Transplant Rep       Date:  2016-05-17

5.  Intraportal Islet Autotransplantation Independently Improves Quality of Life After Total Pancreatectomy in Patients With Chronic Refractory Pancreatitis.

Authors:  Srinath Chinnakotla; Gregory J Beilman; David Vock; Martin L Freeman; Varvara Kirchner; Ty B Dunn; Timothy L Pruett; Stuart K Amateau; Guru Trikudanathan; Sarah J Schwarzenberg; Elissa Downs; Matthew Armfield; Karthik Ramanathan; David E R Sutherland; Melena D Bellin
Journal:  Ann Surg       Date:  2022-06-28       Impact factor: 13.787

Review 6.  Defining outcomes for β-cell replacement therapy in the treatment of diabetes: a consensus report on the Igls criteria from the IPITA/EPITA opinion leaders workshop.

Authors:  Michael R Rickels; Peter G Stock; Eelco J P de Koning; Lorenzo Piemonti; Johann Pratschke; Rodolfo Alejandro; Melena D Bellin; Thierry Berney; Pratik Choudhary; Paul R Johnson; Raja Kandaswamy; Thomas W H Kay; Bart Keymeulen; Yogish C Kudva; Esther Latres; Robert M Langer; Roger Lehmann; Barbara Ludwig; James F Markmann; Marjana Marinac; Jon S Odorico; François Pattou; Peter A Senior; James A M Shaw; Marie-Christine Vantyghem; Steven White
Journal:  Transpl Int       Date:  2018-04       Impact factor: 3.782

Review 7.  Pancreas Islet Transplantation for Patients With Type 1 Diabetes Mellitus: A Clinical Evidence Review.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2015-09-01

Review 8.  Felix dies natalis, insulin… ceterum autem censeo "beta is better".

Authors:  Lorenzo Piemonti
Journal:  Acta Diabetol       Date:  2021-05-23       Impact factor: 4.280

9.  Characterization of pre-transplant psychosocial burden in an integrated national islet transplant program.

Authors:  Aaron Yl Liew; Elizabeth Holmes-Truscott; Anneliese Js Flatt; Denise Bennett; Robert Crookston; Mirka Pimkova; Linda Birtles; John Casey; Andrew Pernet; Ruth C Wood; Pratik Choudhary; Shareen Forbes; Martin K Rutter; Miranda Rosenthal; Paul Johnson; James Am Shaw; Jane Speight
Journal:  Islets       Date:  2020-08-20       Impact factor: 2.694

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.